Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.
A group of immune cells that normally protect against inflammation in the gastrointestinal tract may have the opposite effect in multiple sclerosis (MS) and other brain inflammation-related conditions, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Antibody protection against harmful forms of fungi in the gut may be disrupted in some patients with Crohn’s disease—a condition caused by chronic inflammation in the bowel—according to a new study by Weill Cornell Medicine investigators.
COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.
Weill Cornell Medicine has been awarded a five-year, $28.5 million Martin Delaney Collaboratory grant from the National Institutes of Health to lead a multi-institutional effort aimed at finding a cure for HIV.
A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago.
Weill Cornell Medicine’s Office of Diversity and Inclusion has been recognized as a Diversity Champion by Crain’s New York Business as part of its first annual Excellence in Diversity and Inclusion Awards, announced July 15.
The genetic changes that underlie an especially lethal type of prostate cancer have been revealed in a new study by investigators at Weill Cornell Medicine. Learning more about what causes this type of cancer, called neuroendocrine prostate cancer (NEPC), could lead to new approaches for treating it.
Building on a legacy of groundbreaking advances in medicine and science, Weill Cornell Medicine today launched an ambitious $1.5 billion campaign—with more than $750 million already raised—that will harness emerging biomedical innovations to bring exemplary care to patients and create enduring change in medicine.
The Weill Cornell Graduate School of Medical Sciences honored the Class of 2021 for their academic achievements during a virtual convocation ceremony May 19.
A team led by researchers at Weill Cornell Medicine and Children’s National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.
Dr. Giovanni Manfredi, the Finbar and Marianne Kenny Professor in Clinical and Research Neurology at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute, has received an Outstanding Investigator Award (R35) from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS) to study the role of mitochondrial dysfunction in brain disease.
Gut bacteria play an important role in the body’s response to treatment for tuberculosis (TB), according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering.
A team led by scientists at Weill Cornell Medicine has made a map identifying all the different RNA molecules that are derived from each gene in the brains of mice.
A gene linked to unusually long lifespans in humans protects brain stem cells from the harmful effects of stress, according to a new study by Weill Cornell Medicine investigators.
